Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...
Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned...
Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...
Thermo Fisher Scientific Inc., a titan in the US device industry and listed on the...
In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered...
China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...
LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced...
China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a...
In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against...
Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...